Personalized medicine in inflammatory cardiomyopathy
Balram Neupane1, Qifeng Zhou1, Meinrad Gawaz1
1Department of Cardiology & Cardiovascular Diseases, Eberhard Karls University, Tübingen, Germany.
Personalized Medicine
|May 2, 2018
Summary
Persistent myocardial inflammation, known as inflammatory cardiomyopathy, can lead to chronic heart failure in up to 20% of acute myocarditis patients. Understanding disease mechanisms and individual factors is key for effective treatment and restoring cardiac function.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Inflammatory cardiomyopathy stems from persistent myocardial inflammation, with infectious or noninfectious origins.
- While many acute myocarditis cases resolve, a significant portion (up to 20%) progress to chronic heart failure.
- Individualized disease mechanisms involve complex interactions between host factors and triggering agents.
Purpose of the Study:
- To elucidate the mechanisms underlying inflammatory cardiomyopathy.
- To identify pathways for comprehensive, individualized treatment approaches.
- To explore strategies for preventing the transition from acute inflammation to chronic heart failure.
Main Methods:
- Utilizing inflammatory biomarkers for detection.
- Employing histology and immunohistochemistry for tissue analysis.
- Leveraging advanced imaging and molecular high-throughput sequencing techniques for pathway identification.
Main Results:
- Identification of key disease pathways through integrated diagnostic approaches.
- Establishment of comprehensive diagnostic criteria for inflammatory cardiomyopathy.
- Demonstration of potential therapeutic targets for intervention.
Conclusions:
- Individualized treatment strategies, including anti-inflammatory and antiviral medications alongside heart failure therapy, are crucial.
- Early and accurate diagnosis can prevent the progression to persistent heart failure.
- Restoring cardiac function is achievable through tailored therapeutic interventions.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
509
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
509
01:29Cardiomyopathy V: Interprofessional Care
462
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
462
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
575
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
575
01:30Cardiomyopathy II: Dilated Cardiomyopathy
575
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
575
01:25Cardiomyopathy I: Introduction and Classification
613
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
613
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K